News
StockStory.org on MSN5h
5 Revealing Analyst Questions From Eli Lilly’s Q1 Earnings CallEli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...
Eli Lilly's obesity and Type 2 diabetes drug, Mounjaro, has gained approval from the Indian drug control authority for its ...
6don MSN
Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...
Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...
inews.co.uk on MSN2d
No Mounjaro, GPs tell patients, unless you hit four criteria – and you’re very luckyGPs and pharmacists have warned it will be impossible to meet soaring demand for weight-loss jabs following their rollout on ...
Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...
Zacks Investment Research on MSN6d
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback